[PDF][PDF] A pan-cancer transcriptome analysis reveals pervasive regulation through alternative promoters
Most human protein-coding genes are regulated by multiple, distinct promoters, suggesting
that the choice of promoter is as important as its level of transcriptional activity. However, …
that the choice of promoter is as important as its level of transcriptional activity. However, …
[HTML][HTML] First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes
…, C Dayan, B Keymeulen, KR Owen, M Kindermans… - BMC medicine, 2023 - Springer
Background Type 1 diabetes (T1D) is a CD4 + T cell-driven autoimmune disease characterized
by the destruction of insulin-producing pancreatic β-cells by CD8 + T cells. Achieving …
by the destruction of insulin-producing pancreatic β-cells by CD8 + T cells. Achieving …
Artificial intelligence–based biomarkers of response to immunotherapy in patients with non–small-cell lung cancer considering previous lines of treatment.
…, J Fayette, JP Foy, A Karabajakian, M Kindermans… - 2023 - ascopubs.org
e14652 Background: Lung cancer is one of the most prevalent types of cancer worldwide:
250,000 new cases are diagnosed yearly in the US, amongst which 80% are non-small cell …
250,000 new cases are diagnosed yearly in the US, amongst which 80% are non-small cell …
When adversarial examples are excusable
PJ Kindermans, C Staats - arXiv preprint arXiv:2204.11985, 2022 - arxiv.org
Neural networks work remarkably well in practice and theoretically they can be universal
approximators. However, they still make mistakes and a specific type of them called adversarial …
approximators. However, they still make mistakes and a specific type of them called adversarial …
A pan cancer analysis of promoter activity highlights the regulatory role of alternative transcription start sites and their association with noncoding mutations
Most human protein-coding genes are regulated by multiple, distinct promoters, suggesting
that the choice of promoter is as important as its level of transcriptional activity. While the role …
that the choice of promoter is as important as its level of transcriptional activity. While the role …
A Pan-Cancer Transcriptome Analysis Reveals Pervasive Regulation through Tumor-Associated Alternative Promoters
Most human protein-coding genes are regulated by multiple, distinct promoters, suggesting
that the choice of promoter is as important as its level of transcriptional activity. While the role …
that the choice of promoter is as important as its level of transcriptional activity. While the role …
Study of the mechanism of action of Blarcamesine (ANAVEX® 2‐73): Whole blood transcriptomics analysis identifies treatment impact on compensatory pathways by …
C Williams, M Kindermans, F Parmentier… - Alzheimer's & …, 2023 - Wiley Online Library
Background Blarcamesine (ANAVEX®2‐73), a novel oral selective sigma‐1 receptor (SIGMAR1)
agonist was investigated in a clinical Phase 2a study in Alzheimer’s disease in which …
agonist was investigated in a clinical Phase 2a study in Alzheimer’s disease in which …
[CITATION][C] O2‐05‐02: COMBINING OMICS AND COGNITIVE TESTS DATA FROM THE INSIGHT PRE‐AD STUDY: ARTIFICIAL INTELLIGENCE TECHNOLOGY …
M Kindermans, M Afshar, PA Chiesa… - Alzheimer's & …, 2019 - Wiley Online Library
Background The early detection of cognitively normal individuals with multifactorial risk of
developing Alzheimer's disease (AD), is an essential step to increase the rate of success of …
developing Alzheimer's disease (AD), is an essential step to increase the rate of success of …
[CITATION][C] O5‐07‐04: COMBINING OMICS AND IMAGING DATA FROM THE INSIGHT PRE‐AD STUDY: ARTIFICIAL INTELLIGENCE TECHNOLOGY IDENTIFIES …
M Kindermans, M Afshar, PA Chiesa… - Alzheimer's & …, 2019 - Wiley Online Library
Background The functioning of the basal forebrain (BF) cholinergic system and the
hippocampus, as well as the brain metabolism are likely to be impaired in individuals at risk for …
hippocampus, as well as the brain metabolism are likely to be impaired in individuals at risk for …
[CITATION][C] O2‐05‐03: CHARACTERIZATION AND TRANSFER OF A NOVEL PLASMA Aβ1‐42/Aβ1‐40 SIMOA ASSAY FOR INTEGRATION INTO THE CLINIC
E Stoops, IMW Verberk, AMW Koelewijn… - Alzheimer's & …, 2019 - Wiley Online Library
Background Plasma Aβ1-42/Aβ1-40 is considered as a candidate biomarker to support drug
development programs via patient enrichment in clinical trials. In-depth characterization of …
development programs via patient enrichment in clinical trials. In-depth characterization of …